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● The rapid approval of two anti-CD19 chimeric antigen receptor (CAR) T-cell
therapies and advanced development of anti-BCMA CAR T-cell therapy
demonstrates the potential of the approach in B-cell malignancies. However,
targets with a similar profile for CAR T-cell therapy in other diseases including
acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are lacking.
● CYAD-01 is an autologous CAR T-cell therapy engineered with a multi-
complex, second-generation NKG2D CAR comprising the full-length human
natural killer group 2D (NKG2D) receptor fused to the intracellular domain of
CD3ζ.
● The NKG2D receptor targets 8 ligands (MHC class I chain related proteins A
[MICA] and B [MICB] and unique long 16 binding proteins [ULBP] 1–6 ligands)
found at high frequency across a range of malignancies. Interestingly, non-
malignant cells within the tumor microenvironment (myeloid-derived
suppressor cells, regulatory T-cells and neo-endothelial cells) also express
NKG2D ligands which led in preclinical models to the induction by CYAD-01 of a
broader anti-tumor response beyond direct cancer cell killing.
● CYAD-01 is being evaluated in relapsed/refractory (r/r) AML/MDS patients, with
the objective to define whether the optimal CYAD-01 treatment is with prior
preconditioning chemotherapy (DEPLETHINK study, here discussed) or without
any pretreatment (see THINK study, poster 3826).
● The open-label Phase I/II DEPLETHINK Study (NCT03466320) evaluates a single
infusion of the autologous CYAD-01 administered after a non-myeloablative
preconditioning chemotherapy in r/r AML or MDS patients.
● The preconditioning chemotherapy consists of 300 mg/m² cyclophosphamide
and 30 mg/m² fludarabine daily for 3 days (CyFlu). This preconditioning
chemotherapy should (i) favor the proliferation and expansion of CAR T-cells and
(ii) increase the NKG2D ligand expression in tumor tissues targeted by CYAD-01.
● Dose escalation segment with a Fibonacci 3+3 design:
o Three dose levels (DL) of CYAD-01: 1x108, 3x108 and 1x109 cells per
infusion administered as a single infusion after the preconditioning
chemotherapy,
o The first DL of CYAD-01 was selected at low dose of cells (~ 1.5x106/kg) for
safety precaution as first-time-in human infusion of an NKG2D CAR T-cell
post chemotherapy,
o The first DL of CYAD-01 was evaluated at two intervals between
preconditioning and CYAD-01 infusion (last preconditioning treatment
administered 7 days (T7) or 3 days (T3) before CYAD-01 infusion) to
evaluate any potential modulation of the CYAD-01 cell engraftment,
o Potential CYAD-01 consolidation cycle of 3 infusions every two weeks
without prior preconditioning chemotherapy in the absence of progressive
disease (PD) one month after the first CYAD-01 infusion.
● Primary endpoint of the dose escalation segment is the occurrence of dose-
limiting toxicity (DLT) during the CYAD-01 treatment phase. Key secondary
endpoints include additional safety parameters, CYAD-01 cell kinetics, objective
responses and duration of responses.
● A potential Phase II segment is planned according to specific futility analysis at
the end of the dose escalation segment.
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T a b l e  1 :  P a t i e n t  c h a r a c t e r i s t i c s
DEPLETHINK STUDY
CONCLUSIONS
● To date, the results demonstrate the safety of 1x108 and 3x108 mAb-manufactured CYAD-01
cells/infusion administered after cyclophosphamide/fludarabine preconditioning chemotherapy.
● The preconditioning regimen increases the engraftment of the CYAD-01 cells as compared to cells
infused with no preconditioning, and, for the two first DLs evaluated, the CYAD-01 cell engraftment is
dose-dependent.
● In a preclinical model, CYAD-01 produced with an optimized manufacturing process (“OptimAb”)
showed an improved long-term anti-tumor activity at the same dose as compared to the currently used
process.
● The DEPLETHINK study has been reinitiated at DL-2 with the OptimAb-manufactured CYAD-01
product, which should help to increase expansion of the cells and favor long-term anti-tumor activity.
● In parallel, the OptimAb-manufactured CYAD-01 will be also evaluated without prior preconditioning
therapy (poster 3826) and a next-generation NKG2D CAR, CYAD-02, which includes features further
favoring the persistence of the CAR T-cells in vivo, will be evaluated into the CYCLE-1 Phase I study
(NCT04167696) post preconditioning chemotherapy (poster 3931), both in the same patient population.
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T a b l e  2 :  I n c i d e n c e  o f  t r e a t m e n t - r e l a t e d  a d v e r s e  e v e n t s  ( A E s )  i n  p a t i e n t s  i n f u s e d  w i t h  C Y A D - 0 1  p r o d u c e d  w i t h  t h e  c u r r e n t  m A b m a n u f a c t u r i n g  p r o c e s s
Study snapshot: 19 Nov 2019
All patients DL-1 DL2
1x108 3x108
N = 9 N=6 N=3
Age (years): Mean (Range) 63.6 (50-73) 61.7 (50-73) 67.3 (58-73)
Gender: Male/Female 6/3 4/2 2/1
ECOG performance score at screening  (Grade 0/1/2) 5/3/1 4/2/0 1/1/1
LVEF (%): Mean (Range) 57.7 (45-66) 56.5 (45-65) 60.0 (54-66)
Tumor type       
r/r  Acute Myeloid Leukemia 7 4 3
r/r Myelodysplastic Syndrome 2 2 0
ELN 2017/R-IPSS Risk Stratification for AML/MDS
Favorable (AML)/Intermediate (MDS) 0/0 0/0 0/0
Intermediate (ALM)/High-Risk (MDS) 3/0 1/0 2/0
Adverse (AML)/Very High-Risk (MDS) 4/2 3/2 1/0
Bone marrow blasts (%)  mean (range)                                              26.0 (3.0-48.0) 28.0 (6.0-48.0) 22.0 (3.0-38.0)
Platelets (103/μL) mean (range)                                       64.2 (21.0-156.0) 80.2 (45.0-156.0) 32.3 (21.0-43.0)
ANC (103/μL) mean (range)                                       1.83 (0-8.7) 2.7 (0-8.7) 0.2 (0-0.38)
Study snapshot: 19 Nov 2019
Adverse Event (AE) Preferred Term

















All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4
Total of patients with at least 1 related AE (%) 3 (50.0%) - - 2 (100.0%) 1 (50.0%)(1) 1 (50.0%) (1) 1 (33.3%) - - 1 (100.0%) 1 (100.0%) -
Cytokine release syndrome 3 (50.0%) - - 2 (100.0%) - 1 (50.0%) (1) 1 (33.3%) - - 1 (100.0%) 1 (100.0%) -
Encephalopathy - - - 1 (50.0%) 1 (50.0%) (1) - - - - - - -
Hyperglycaemia - - - 1 (50.0%) 1 (50.0%) (1) - - - - - - -
Abdominal Distension - - - 1 (50.0%) - - - - - - - -
Agitation - - - 1 (50.0%) - - - - - - - -
Chills - - - - - - - - - 1 (100.0%) - -
Cough - - - - - - - - - 1 (100.0%) - -
Diarrhoea 1 (16.6%) - - - - - 1 (33.3%) - - - - -
Disseminated intravascular coagulation - - - 1 (50.0%) - - - - - - - -
Hyperphosphataemia - - - 1 (50.0%) - - - - - - - -
Hypocalcaemia - - - 1 (50.0%) - - - - - - - -
Non-cardiogenic pulmonary oedema - - - - - - - - - 1 (100.0%) - -
Sepsis syndrome - - - - - - - - - 1 (100.0%) - -
F i g u r e  1 :  C Y A D - 0 1  k i n e t i c s  i n  t h e  p e r i p h e r a l  b l o o d  
( h i g h e s t  p e a k )
F i g u r e  4 :  I n  v i v o a n t i - t u m o r  a c t i v i t y  o f  
C Y A D - 0 1  T - c e l l s  m a n u f a c t u r e d  w i t h  
t h e  m A b o r  O p t i m A b  p r o c e s s
F i g u r e  2 :  C Y A D - 0 1  C D 8 +  T - c e l l s  m a n u f a c t u r e d  w i t h  
t h e  m A b o r  O p t i m A b  p r o c e s s  p r e s e n t  a n  
e a r l y  p h e n o t y p e  ( C D 4 5 R A / C D 2 7  l a b e l i n g )
(1) Consolidation cycle at the 3x109 cells/infusion 
F i g u r e  3 :  C Y A D - 0 1  C D 8 +  T - c e l l s  m a n u f a c t u r e d  w i t h  
t h e  m A b o r  O p t i m A b  p r o c e s s  p r e s e n t  a n  
e a r l y  p h e n o t y p e  ( C D 6 2 L  l a b e l i n g )
Effector memory T-cells (CD45RA-/CD27-)
Terminal effector T-cells (CD45RA+/CD27-)
Naïve or stem cell memory T-cells (CD45RA+/CD27+)
Central memory T-cells (CD45RA-/CD27+) Mice bearing an aggressive AML (THP-1) cell line received
3 weekly injections of 3 x 106 Mock, CYAD-01 mAb or
CYAD-01 OptimAb T-cells per infusion. This dose was
titrated for minimal activity of CYAD-01 mAb.
● Study Status (Table 1):
o 9 patients have been enrolled so far in the two first DLs of the dose escalation segment of this
Phase I study with the current mAb process,
o The recruitment has been re-initiated at DL-2 with the OptimAb-manufactured CYAD-01 for
safety and cell kinetics comparability reasons (ongoing, data not shown).
● An encouraging safety profile was observed (Table 2) for all CYAD-01 infusions post CyFlu
preconditioning chemotherapy. To note, at the 1st CYAD-01 infusion of the consolidation cycle (3x109
cells per infusion), 1 patient at DL-1 (T7) experienced a Grade (G) 4 cytokine release syndrome (CRS) and
a G3 CAR T-cell-related encephalopathy syndrome (CRES) and 1 patient at DL-2 experienced a G3 CRS.
All patients recovered with treatment including tocilizumab.
● No objective response has been observed at the first two DLs but 3/9 patients did not progress one
month after the first CYAD-01 infusion and were eligible for the consolidation cycle.
● For the two first DLs evaluated with the mAb process, the CYAD-01 cell engraftment is dose-dependent
(Figure 1), and the addition of the CyFlu as preconditioning induces a better time-averaged engraftment
as compared to the CYAD-01 injected without preconditioning (Figure 1 and THINK poster 3826).
MAIN RESULTS
OPTIMIZED MANUFACTURING PROCESS
● With respect to the CYAD-01 product, the current manufacturing process (mAb process), used to date
in the DEPLETHINK study, tends to produce more differentiated T-cells that are highly active in killing
but less able to persist. There is an emerging view in the cell therapy field that T-cells with reduced
differentiation may be more active in the therapeutic setting.
● Celyad has developed a new process named “OptimAb”, which generates a higher frequency of less
differentiated CYAD-01 T-cells as compared to previous process (Figures 2 and 3). The OptimAb
manufactured cells also produce higher levels of interferon gamma upon challenge with tumor cells.
● In a preclinical model, the OptimAb-manufactured CYAD-01 showed much improved long-term anti-
tumor activity as compared to the currently used mAb-manufactured CYAD-01 at the same dose of
cells (Figure 4).
